With new generic rivals, Lipitor's sales halved

By LINDA A. JOHNSON , AP Business writer

Sales of cholesterol blockbuster Lipitor plunged by half barely a week after the world's top-selling drug got its first U.S. generic competition, new data show.

That's despite a very aggressive effort by maker . to keep patients on its pill, which generated peak sales of $13 billion a year, through patient subsidies and big rebates to insurers.

Lipitor lost on Nov. 30 in the U.S., where the drug was still generating about $7.9 billion in annual sales. Two generic versions costing about a third less hit the market right away, one made by India's Ranbaxy Laboratories Ltd. and the other an authorized generic, made by Pfizer and sold by its partner, Watson Pharmaceuticals Inc.

Lipitor's patent loss has been closely watched across the pharmaceutical industry, where most companies face , and a big revenue hit, for at least some of their top drugs over the next few years.

Figures from data firm IMS Health on prescriptions for Lipitor and competing drugs that lower LDL or , the class called statins, show the number of Lipitor prescriptions filled in the seven days ended Dec. 9, the first full week when generic rivals were available, plunged to 359,235. That's down from the 724,799 Lipitor prescriptions filled a month earlier, in the week ended Nov. 11.

Lipitor's share of statin prescriptions dropped to 9.7 percent from 20.9 percent over that period. Its biggest rival among brand-name is a newer one, Crestor from Britain's AstraZeneca PLC, which saw market share hold steady at 12.3 percent amid a new Crestor ad campaign.

The IMS data, released Monday, show nearly 476,000 new prescriptions for generic Lipitor, called atorvastatin, were filled the week ended Dec. 9. Just under 80 percent were for Watson's generic version.

The figures cover retail prescriptions, those filled at independent pharmacies, chain drug stores and pharmacies in supermarkets and discounters such as Target. Not included are prescriptions filled by mail order, where any shifts are likely to take longer to appear.

Miller Tabak analyst Les Funtleyder said Monday the drop in Lipitor prescriptions is less than he expected.

"It's already done better than we thought it would, (but) it's a little early in the game to declare this a successful strategy," Funtleyder, portfolio manager for the Miller Tabak Health Care Transformation Fund, said of Pfizer's rebates and discounts.

For months, New York-based Pfizer has been heavily advertising its "Lipitor For You" program, which offers insured patients a card to get Lipitor for a monthly $4 copayment. Pfizer will pay the difference between that and an insurance plan's normal brand-name co-pay, up to $50.

Uninsured patients could get the same savings using the card but would have to pay the rest of the cost, which ranges from about $115 a month for the lowest Lipitor dose to $160 a month for three higher doses. The new generics cost roughly $80 and $100 a month, respectively.

Spokesman MacKay Jimeson said Pfizer estimates about 5 percent of current Lipitor patients in the U.S. and Puerto Rico will enroll in the program.

Many of the roughly 3 million Americans who were taking Lipitor have not gotten a refill since generic Lipitor arrived. For some, their insurance plan may not give them a choice - either automatically switching them to generic Lipitor or keeping them on the brand name and taking Pfizer's rebates for the next six months.

After that, multiple generic versions will hit the market. Their prices should dip as low as about 20 percent of brand-name Lipitor, and the Pfizer discounts will end.

Any market share retained until then is worth a lot to Pfizer, Funtleyder said, noting the low cost of making the pills - about a dime each.

"It wouldn't surprise me to see similar things from other companies," he said, if Pfizer's program continues to retain some patients.

While Lipitor and Crestor generate most of the money from cholesterol medicines, much-cheaper of three older statins - Zocor, Pravachol and Mevacor - account for almost two-thirds of statin prescriptions. Those three generics saw a slight increase in the number of prescriptions filled from Nov. 11 to Dec. 9.

According to IMS, about 167,000 of the prescriptions filled for atorvastatin were from patients who had been on Lipitor, another 118,000 were from people on simvastatin (generic Zocor) and about 20,000 were from patients on Crestor. The rest were from the other existing generic statins and seven other brand-name statins that have very low sales, most because they have a generic rival.

Overall, the number of people taking a statin drug increased slightly right after generic Lipitor arrived. The number of prescriptions filled for statins jumped from about 3.48 million in the week ended Nov. 11, to 3.7 million in the week ended Dec. 9.

Jason Mazzarella, a product manager at IMS Health, thinks that's partly because patients with tight budgets are more likely to go without cholesterol pills than drugs for conditions with obvious symptoms, and generic Lipitor would be more affordable for them.

Also, some of the new prescriptions are for patients adding it to another statin or one of the eight other types of drugs for cholesterol problems.

Besides Pfizer, AstraZeneca stands to lose most from generic Lipitor. It started a new advertising campaign in November, with broadcast, print, Internet and other ads. It will continue into 2012, AstraZeneca spokeswoman Elizabeth Renz said.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer's blockbuster drug Lipitor goes generic

Nov 30, 2011

Pfizer's patent on the best-selling drug of all-time, the cholesterol-lowering medication Lipitor, expired on Wednesday, opening the path to generic competitors for America's most popular medication.

Pfizer maneuvers to protect Lipitor from generics

Nov 29, 2011

(AP) -- Lipitor is so valuable that its maker, Pfizer Inc., is practically paying people to keep taking the blockbuster cholesterol medicine after generic competition hits the U.S. market this week.

Americans turn to generic medications in 2010: report

Apr 22, 2011

(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Pfizer gets EU approval for kids' cholesterol drug

Jul 06, 2010

(AP) -- The European Union has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol and triglycerides, a type of blood fat, Pfizer said Tuesday.

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

dogbert
1 / 5 (1) Dec 20, 2011
Overall, the number of people taking a statin drug increased slightly right after generic Lipitor arrived. The number of prescriptions filled for statins jumped from about 3.48 million in the week ended Nov. 11, to 3.7 million in the week ended Dec. 9.


Unfortunately, the number of prescriptions for statins is still increasing. It is difficult to understand why the insurance companies and government programs continue to fund this scam.
Vendicar_Decarian
1 / 5 (1) Dec 20, 2011
It seems that almost everything is a "Scam" to DogBerTard.

Well. Everything accept Rampant Republicanism and Chewin Tabakki..
dogbert
1 / 5 (1) Dec 20, 2011
No Vendi. Everything is not a scam. Statins are a massive scam.

There its not one valid study that supports the claim that modifying cholesterol levels has any benefit whatsoever and stains are dangerous and costly drugs.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.